Using prophylaxis with biosimilar granulocyte colony-stimulating factor can reduce the severity of neutropenia in patients with soft tissue sarcoma.
Using prophylaxis with biosimilar granulocyte colony-stimulating factor (G-CSF) can reduce the severity of neutropenia in patients with soft tissue sarcoma, according to a study published in Supportive Care in Cancer.
For both early and advanced settings in soft tissue sarcoma, anthracycline and ifosfamide-based chemotherapy is a widely used regimen, and prophylaxis with G-CSF is usually needed to reduce the severity of chemotherapy-induced neutropenia. Italian researchers set out to determine the efficacy and safety of using the biosimilar G-CSF filgrastim in these patients.
A total of 67 patients receiving biosimilar filgrastim (US: Zarxio; Europe: Zarzio), originator filgrastim (Granulokine, Neupogen), and lenograstim (Myelostim; not approved in the United States) as primary prophylaxis were analyzed. They received a total of 360 cycles of therapy and were analyzed retrospectively.
The researchers determined that biosimilar G-CSF was effective in preventing febrile neutropenia and reducing the need for hospitalization in patients with soft tissue sarcoma undergoing epirubicin and ifosfamide treatment. Febrile neutropenia occurred in 44% of patients on biosimilar filgrastim, 40% of patients on originator filgrastim, and 45.5% of patients in the lenograstim group.
Safety profiles across the 3 groups were similar. However, using biosimilar filgrastim achieved savings of €225.25 ($251.50) over originator filgrastim and €262 ($292.54) over lenograstim.
Biosimilar G-CSF “proved comparable to its reference products from both a clinical and cost-effective standpoint,” the authors concluded.
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More